search
The following results are related to Canada. Are you interested to view more results? Visit OpenAIRE - Explore.
3 Projects, page 1 of 1

  • Canada
  • 2021-2021
  • European Commission
  • 2017
  • 2021

  • Open Access mandate for Publications
    Funder: EC Project Code: 733296
    Overall Budget: 2,231,440 EURFunder Contribution: 2,149,200 EUR
    Partners: NCN, MINISTERSTWO NAUKI I SZKOLNICTWA WYZSZEGO, UKRI, MINISTERIO DE CIENCIA, TECNOLOGIA E INNOVACION, IC, ANR, CSO-MOH, MCTeIP, BMBF, ISCIII...

    EXEDRA, an EXpansion of the European Joint Programming Initiative on Drug Resistance to Antimicrobials, will build on, and further support the structure and activities of JPIAMR to address the two major objectives of HCO-04-2016 topic: extending JPIAMR globally and creating a long-term sustainable structure for future expansion and governance which will coordinate national funding and collaborative actions supporting the implementation of the JPIAMR Strategic Research Agenda (SRA). JPIAMR EXEDRA will be the second Coordinated Support Action (CSA) for this Joint Programming Initiative (JPI) and essentially build on the work of the first CSA (JPIAMR), which ended February 2016. It will provide a strong support structure for the JPIAMR during the forthcoming implementation and expansion phaseby maintaining a continuity between the objectives, tasks and Work Packages of EXEDRA and JPIAMR. Support facilitated by the CSA EXEDRA will ensure that the ethos of joint programming in the area antimicrobial drug resistance becoming embedded within JPIAMR member’s research and innovation policies and programmes. EXEDRA will have the following work packages: WP1 Management and coordination; WP2 Strategy, governance, and long term sustainability; WP3 Internationalisation and capacity extension; WP4 Alignment with policy and industry; WP5 Research alignment; WP6 Communication, dissemination, and advocacy. EXEDRA will significantly contribute to the delivery of the JPIAMR SRA combined with the JPI-EC-AMR effort and the experience of the JPIAMR members. EXEDRA (and the JPIAMR) will support transnational cooperation to to pool substantial and long-term research funding and serve to complement other initiatives in the AMR area. It will create momentum with the potential to move the frontiers forward and offer new opportunities for industry, new tools for society, and new evidence-based data for policy makers, which will inspire other necessary initiatives.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 730879
    Overall Budget: 4,968,250 EURFunder Contribution: 4,955,880 EUR
    Partners: UMCG, TAU, MHH, UKRI, University of Sheffield, CNR, UAB, CNRS, CSIC, FUNDACAO CALOUSTE GULBENKIAN...

    The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse models for basic research of human health and disease, and to translate this knowledge into therapeutic approaches for the benefit of the European society. The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER GmbH, includes 3 SMEs and is strategically responding to the INFRADEV3 call with aligned objectives to advance the long-term sustainability which are 1) development of business models and a stable legal framework; 2) raise awareness of the INFRAFRONTIER RI; 3) provide bespoke services aligned with user demands; 4) promote best practices in mouse phenogenomics; 5) enhance robustness of the INFRAFRONTIER IT infrastructure and use of the EMMA strain resource; and 6) improve business processes. Towards achieving these objectives key INFRAFRONTIER2020 project deliverables are: • INFRAFRONTIER Business Plan2.0, and business models for all services • Stable legal framework built on the INFRAFRONTIER legal entity • INFRAFRONTIER annual stakeholder conferences • Customised mouse model and secondary phenotyping pilot services • INFRAFRONTIER advanced training schools in mouse phenogenomics • Reengineered EMMA Database2.0 system • Annotated mouse models of human diseases • Quality management system for the legal entity INFRAFRONTIER2020 will 1) enhance the sustainable operation of the INFRAFRONTIER RI; 2) continue to structure the ERA, 3) foster innovation, and 4) address major societal challenges in human health by customised service pilots supporting research into common and rare diseases. A sustainable INFRAFRONTIER RI will ensure the quality of deposited mice and support the reproducibility of biological results. Outreach efforts will raise awareness of resources and services and facilitate sustainable engagement with industry and global consortia such as the International Mouse Phenotyping Consortium

  • Open Access mandate for Publications
    Funder: EC Project Code: 769929
    Overall Budget: 4,948,030 EURFunder Contribution: 4,948,030 EUR
    Partners: Manz (Italy), ARKEMA, Hydro-Québec, FUNDACION CIDETEC, BMW GROUP, VUB, TU GRAZ, VARTA, VARTA Storage GmbH, UMICORE...

    As of today, Europe remains not competitive in terms of Lithium battery cell development and especially manufacturing. This lack of competence and competitiveness could quickly spiral down into a complete loss of this key technology for electrification in the EU. Thus IMAGE will significantly contribute to sustainably develop the European Li-battery cell manufacturing competence and capability by creating a competitive, production-oriented research & development framework within Europe. A realistic and well-documented roadmap towards the manufacturing of cost-effective and competitive battery cells within Europe will emerge. This will be enforced by establishing a distributed battery cell production base that will be able, after careful upscaling of production, to supply the now burgeoning electric vehicle industry. From this context, the main goal of IMAGE is to push European’s Li-battery industry and academia to take over a leading role in the development and manufacturing of Next Generation Li-Ion cells. IMAGE has the following major objectives: 1) Develop generic production techniques for next generation battery cells based on high specific energy Li-metal battery cells. This will include a modular development approach that will be easy to up-scale while remaining flexible and safer to replace in case of any contingencies and market/ manufacturer configuration changes. 2) Identify energy and resource efficient cell manufacturing technologies and assets tailored to the existent European industrial infrastructure. This will include the identification of bottleneck factors and challenges that could be addressed in the present European industrial context. 3) Develop a progressive, multiple-tier technological and production framework that is able to cope with the inherent technological changes and advancements characteristic to this dynamic field. Thus, there will be several technologies covered by IMAGE, each having different technological maturity level.

search
The following results are related to Canada. Are you interested to view more results? Visit OpenAIRE - Explore.
3 Projects, page 1 of 1
  • Open Access mandate for Publications
    Funder: EC Project Code: 733296
    Overall Budget: 2,231,440 EURFunder Contribution: 2,149,200 EUR
    Partners: NCN, MINISTERSTWO NAUKI I SZKOLNICTWA WYZSZEGO, UKRI, MINISTERIO DE CIENCIA, TECNOLOGIA E INNOVACION, IC, ANR, CSO-MOH, MCTeIP, BMBF, ISCIII...

    EXEDRA, an EXpansion of the European Joint Programming Initiative on Drug Resistance to Antimicrobials, will build on, and further support the structure and activities of JPIAMR to address the two major objectives of HCO-04-2016 topic: extending JPIAMR globally and creating a long-term sustainable structure for future expansion and governance which will coordinate national funding and collaborative actions supporting the implementation of the JPIAMR Strategic Research Agenda (SRA). JPIAMR EXEDRA will be the second Coordinated Support Action (CSA) for this Joint Programming Initiative (JPI) and essentially build on the work of the first CSA (JPIAMR), which ended February 2016. It will provide a strong support structure for the JPIAMR during the forthcoming implementation and expansion phaseby maintaining a continuity between the objectives, tasks and Work Packages of EXEDRA and JPIAMR. Support facilitated by the CSA EXEDRA will ensure that the ethos of joint programming in the area antimicrobial drug resistance becoming embedded within JPIAMR member’s research and innovation policies and programmes. EXEDRA will have the following work packages: WP1 Management and coordination; WP2 Strategy, governance, and long term sustainability; WP3 Internationalisation and capacity extension; WP4 Alignment with policy and industry; WP5 Research alignment; WP6 Communication, dissemination, and advocacy. EXEDRA will significantly contribute to the delivery of the JPIAMR SRA combined with the JPI-EC-AMR effort and the experience of the JPIAMR members. EXEDRA (and the JPIAMR) will support transnational cooperation to to pool substantial and long-term research funding and serve to complement other initiatives in the AMR area. It will create momentum with the potential to move the frontiers forward and offer new opportunities for industry, new tools for society, and new evidence-based data for policy makers, which will inspire other necessary initiatives.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 730879
    Overall Budget: 4,968,250 EURFunder Contribution: 4,955,880 EUR
    Partners: UMCG, TAU, MHH, UKRI, University of Sheffield, CNR, UAB, CNRS, CSIC, FUNDACAO CALOUSTE GULBENKIAN...

    The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse models for basic research of human health and disease, and to translate this knowledge into therapeutic approaches for the benefit of the European society. The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER GmbH, includes 3 SMEs and is strategically responding to the INFRADEV3 call with aligned objectives to advance the long-term sustainability which are 1) development of business models and a stable legal framework; 2) raise awareness of the INFRAFRONTIER RI; 3) provide bespoke services aligned with user demands; 4) promote best practices in mouse phenogenomics; 5) enhance robustness of the INFRAFRONTIER IT infrastructure and use of the EMMA strain resource; and 6) improve business processes. Towards achieving these objectives key INFRAFRONTIER2020 project deliverables are: • INFRAFRONTIER Business Plan2.0, and business models for all services • Stable legal framework built on the INFRAFRONTIER legal entity • INFRAFRONTIER annual stakeholder conferences • Customised mouse model and secondary phenotyping pilot services • INFRAFRONTIER advanced training schools in mouse phenogenomics • Reengineered EMMA Database2.0 system • Annotated mouse models of human diseases • Quality management system for the legal entity INFRAFRONTIER2020 will 1) enhance the sustainable operation of the INFRAFRONTIER RI; 2) continue to structure the ERA, 3) foster innovation, and 4) address major societal challenges in human health by customised service pilots supporting research into common and rare diseases. A sustainable INFRAFRONTIER RI will ensure the quality of deposited mice and support the reproducibility of biological results. Outreach efforts will raise awareness of resources and services and facilitate sustainable engagement with industry and global consortia such as the International Mouse Phenotyping Consortium

  • Open Access mandate for Publications
    Funder: EC Project Code: 769929
    Overall Budget: 4,948,030 EURFunder Contribution: 4,948,030 EUR
    Partners: Manz (Italy), ARKEMA, Hydro-Québec, FUNDACION CIDETEC, BMW GROUP, VUB, TU GRAZ, VARTA, VARTA Storage GmbH, UMICORE...

    As of today, Europe remains not competitive in terms of Lithium battery cell development and especially manufacturing. This lack of competence and competitiveness could quickly spiral down into a complete loss of this key technology for electrification in the EU. Thus IMAGE will significantly contribute to sustainably develop the European Li-battery cell manufacturing competence and capability by creating a competitive, production-oriented research & development framework within Europe. A realistic and well-documented roadmap towards the manufacturing of cost-effective and competitive battery cells within Europe will emerge. This will be enforced by establishing a distributed battery cell production base that will be able, after careful upscaling of production, to supply the now burgeoning electric vehicle industry. From this context, the main goal of IMAGE is to push European’s Li-battery industry and academia to take over a leading role in the development and manufacturing of Next Generation Li-Ion cells. IMAGE has the following major objectives: 1) Develop generic production techniques for next generation battery cells based on high specific energy Li-metal battery cells. This will include a modular development approach that will be easy to up-scale while remaining flexible and safer to replace in case of any contingencies and market/ manufacturer configuration changes. 2) Identify energy and resource efficient cell manufacturing technologies and assets tailored to the existent European industrial infrastructure. This will include the identification of bottleneck factors and challenges that could be addressed in the present European industrial context. 3) Develop a progressive, multiple-tier technological and production framework that is able to cope with the inherent technological changes and advancements characteristic to this dynamic field. Thus, there will be several technologies covered by IMAGE, each having different technological maturity level.